Your browser doesn't support javascript.
loading
Use of natalizumab in persons with multiple sclerosis: 2022 update.
Morrow, Sarah A; Clift, Fraser; Devonshire, Virginia; Lapointe, Emmanuelle; Schneider, Raphael; Stefanelli, Mark; Vosoughi, Reza.
Afiliación
  • Morrow SA; Department of Clinical Neurological Sciences, Western University, London, ON, Canada. Electronic address: Sarah.Morrow@lhsc.on.ca.
  • Clift F; Department of Neurology, Memorial University of Newfoundland, St. John's, NL, Canada.
  • Devonshire V; Department of Medicine, Division of Neurology, University of British Columbia, Vancouver, BC, Canada.
  • Lapointe E; Department of Medicine, Division of Neurology, University of Sherbrooke, QC, Canada.
  • Schneider R; Department of Medicine, Division of Neurology, University of Toronto, ON, Canada.
  • Stefanelli M; Department of Neurology, Memorial University of Newfoundland, St. John's, NL, Canada.
  • Vosoughi R; Department of Medicine, Division of Neurology, University of Toronto, ON, Canada.
Mult Scler Relat Disord ; 65: 103995, 2022 Sep.
Article en En | MEDLINE | ID: mdl-35810718
BACKGROUND: Natalizumab is a humanized monoclonal antibody used for treatment of highly active relapsing-remitting multiple sclerosis (MS). With more than 15 years of post-marketing experience with natalizumab in Canada, several real-world studies have shown the long-term efficacy and safety of natalizumab. In addition, risk stratification/mitigation strategies for progressive leukoencephalopathy (PML), an adverse effect associated with natalizumab based on the John Cunningham virus (JCV) index; treatment duration beyond 24 months; and prior exposure to immunosuppressant drugs have been developed. METHODS: A group of neurologists from various MS clinics across Canada met in September 2021 to update the 2015 Canadian practice recommendations for the use of natalizumab in persons with MS (PwMS). RESULTS: The recommendations focused on the long-term efficacy and safety data from real-world studies, patient selection according to JCV index criteria, risk management strategies for PML (including extended interval dosing), and options for switching to currently available disease-modifying therapies for MS. CONCLUSIONS: The recommendations of clinical neurologists seek to optimize the management of PwMS who may benefit from treatment with natalizumab.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Leucoencefalopatía Multifocal Progresiva / Virus JC / Esclerosis Múltiple Recurrente-Remitente / Esclerosis Múltiple Tipo de estudio: Guideline Límite: Humans País/Región como asunto: America do norte Idioma: En Revista: Mult Scler Relat Disord Año: 2022 Tipo del documento: Article Pais de publicación: Países Bajos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Leucoencefalopatía Multifocal Progresiva / Virus JC / Esclerosis Múltiple Recurrente-Remitente / Esclerosis Múltiple Tipo de estudio: Guideline Límite: Humans País/Región como asunto: America do norte Idioma: En Revista: Mult Scler Relat Disord Año: 2022 Tipo del documento: Article Pais de publicación: Países Bajos